Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cell), in Healthy Elderly Aged 60 Years and Above

NCT04383574 is registered in ClinicalTrials.gov with Sinovac Life Sciences Co., Ltd. as lead sponsor.

NCT NCT04383574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04383574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cell), in Healthy Elderly Aged 60 Years and Above
Lead sponsor
Sinovac Life Sciences Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
May 22, 2020
Completion date
May 31, 2022
Enrollment
422 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19